NUCYNTA

LOE Approaching

tapentadol hydrochloride

NDAORALSOLUTION
Approved
Oct 2012
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Clinical Trials
3

Clinical Trials (3)

NCT01719601N/AWithdrawn

A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain

Started Oct 2014
0
Moderate to Severe Acute Non-Cancer Pain
NCT01719588N/AWithdrawn

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

Started Oct 2014
0
Moderate to Severe Chronic Non-cancer Pain
NCT00986180Phase 3Completed

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

Started Sep 2009
667 enrolled
PainBack PainLow Back Pain+1 more

Loss of Exclusivity

LOE Date
Jul 3, 2026
4 months away
Exclusivity Expiry
Jan 3, 2027